168 related articles for article (PubMed ID: 36266430)
1. Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment.
Hayashi S; Matsubara T; Maeda T; Fukuda K; Funahashi K; Hashimoto M; Tsumiyama K; Kamenaga T; Takashima Y; Matsumoto T; Tachibana S; Kuroda R
Sci Rep; 2022 Oct; 12(1):17524. PubMed ID: 36266430
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
Hayashi S; Matsubara T; Fukuda K; Funahashi K; Hashimoto M; Maeda T; Kamenaga T; Takashima Y; Matsumoto T; Niikura T; Kuroda R
Sci Rep; 2020 Oct; 10(1):16645. PubMed ID: 33024253
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
5. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
Giles JT; Sattar N; Gabriel S; Ridker PM; Gay S; Warne C; Musselman D; Brockwell L; Shittu E; Klearman M; Fleming TR
Arthritis Rheumatol; 2020 Jan; 72(1):31-40. PubMed ID: 31469238
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.
Hirabara S; Takahashi N; Fukaya N; Miyake H; Yabe Y; Kaneko A; Ito T; Oguchi T; Kida D; Hirano Y; Fujibayashi T; Sugiura F; Hayashi M; Funahashi K; Hanabayashi M; Asai S; Ishiguro N; Kojima T
Clin Rheumatol; 2014 Sep; 33(9):1247-54. PubMed ID: 24970596
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
[TBL] [Abstract][Full Text] [Related]
13. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
15. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
Rubbert-Roth A; Aletaha D; Devenport J; Sidiropoulos PN; Luder Y; Edwardes MD; Jacobs JWG
Rheumatology (Oxford); 2021 Feb; 60(2):682-691. PubMed ID: 32844216
[TBL] [Abstract][Full Text] [Related]
16. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
18. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
Kaneko A; Kida D; Saito K; Tsukamoto M; Sato T
Rheumatol Int; 2012 Nov; 32(11):3631-7. PubMed ID: 22127466
[TBL] [Abstract][Full Text] [Related]
19. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
20. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
